In The News

Corporate Team Represents Ultragenyx in its IPO

Practices: Life Sciences, Executive Compensation & Employee Benefits

Ropes & Gray represented Ultragenyx Pharmaceuticals, a development-stage biotechnology company focused on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases, in its $120 million initial public offering.

The Ropes & Gray team included benefits counsel Allie Alperovich.

Cookie Settings